Strontium 英 /ˈstrɒntiəm; ˈstrɒnʃiəm/ 美 /ˈstrɑːntiəm,ˈstrɑːnʃiəm/
释 义 n. [化学] 锶
例 句 This paper described the determination of strontium in mineral water by flame atomic emission spectrometry in the emission mode of AAS. 本文介绍了用原子吸收光谱仪的发射方式火焰原子发射光谱法直接测定矿泉水中锶。
释 义 雷奈
例 句 A lot of animal experiments and clinical trials have proven that strontium ranelate not only can prevent bone absorption but also promote bone formation. 大量的动物实验和临床试验研究表明雷奈酸锶是一种既具有抗骨吸收，又能促进骨形成的药物。
作者： Letícia Macedo Marins
期刊：J Periodontal Res
The destruction of the protective and supportive periodontal tissues during the course of periodontitis is a consequence of the interaction between pathogens and immunoinflammatory host responses. There is a continuous interest in identifying risk factors, such as lifestyles, systemic diseases, and medications, that can hinder or accelerate periodontal tissue destruction during periodontitis by modifying the periodontal microbial profile, host responses and/or alveolar bone metabolism. Estrogen deficiency appears naturally after menopause or as a result of early menopause or bilateral oophorectomies and has been identified as one of main causes of osteoporosis. The depletion of estrogen induces a significant imbalance in bone remodeling, with bone resorption exceeding bone formation. The main characteristics of osteoporosis are the reduction of bone mass and mineral contents, alterations in bone micro‐architecture, and increased risk of fractures. Due to the rising prevalence of osteoporosis, researchers and clinicians in the field of dentistry have focused on the study of the impact of osteoporosis on the different bone pathologies that affect the jawbones. In periodontics, clinical studies have suggested a positive association between the clinical and radiographic parameters of periodontitis and the parameters used for the diagnosis of osteoporosis. Studies in animals using ovariectomy‐induced estrogen deficiency models have shown that osteoporosis increases alveolar bone resorption in rats with and without ligature‐induced periodontitis. Currently, bisphosphonates are the most commonly used anti‐ resorptive agents for the treatment of osteoporosis; however, the initiation or continuation of bisphosphonate therapies has declined due to the risk of adverse effects including osteonecrosis of the jaw and atypical fractures. Hence, there is an unceasing search for medications that can effectively treat osteopenia/osteoporosis, reducing the fracture risk at all skeletal sites, with minimal contraindications, maximum tolerability, and the best risk‐benefit balance. During the last decade, several reports have investigated strontium ranelate as an antiosteoporosis drug due to its promising physicochemical and pharmacokinetic features. When compared to other drugs, strontium ranelate has a very peculiar dual action on bone tissues that simultaneously stimulates osteoblast recruitment and activity while the number, activity, and lifespan of osteoclasts are reduced, resulting in both anabolic and anti‐resorptive actions.